$2.85
+0.09 (+3.26%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CERS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 3 observational · 4 with posted results
Held by 13 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, +8 more) · FINRA short interest 5.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated HemorrhageNCT07218185observationalIFC administration within 60 minutes of presentation | — | Not yet recruiting | Biological: Pathogen Reduced Cryoprecipitated Fibrinogen Complex | Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock | 320 | Jul 2028 | ≤ 711 d | 2026-06-17 |
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCsNCT07152379Acute or delayed hemolytic transfusion reactionsNon-randomized · Open-label · Screening | Phase 2 | Not yet recruiting | Device: 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs | Transfusion Reaction, Hemolytic | 10 | 2027-10-01 | in 407 d | 2026-06-08 |
| INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164Adjusted hemoglobin incrementRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Device: INTERCEPT Blood System for Red Blood Cells, Conventional (Control) | Anemia | 692 | 2026-07-31 | — | 2026-03-20 |
| A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1NCT07015437The percentage of infused 35-day-old autologous 51Cr-labeled Test/INTERCEPT or Control RBCs remaining in circulation 24 hours post-infusionRandomized · Single-masked · Other | Phase 2 | Recruiting | Device: INTERCEPT Blood System for RBCs · Other: Infusion of autologous radiolabeled RBCs | Healthy Subjects | 70 | 2026-07-30 | — | 2025-10-15 |
| Biotin-Acridine Red Cell Exchange KineticsNCT07155031RecoveryOpen-label · Supportive care | Phase 2 | Withdrawnsponsor's stated reason: This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes available. | Device: Pathogen reduced red blood cells | Sickle Cell Disease | 0 | 2026-09-30 | in 41 d | 2026-04-09 |
| A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.NCT06697223results2026-08-04Post Infusion Recovery of Test Platelets at End of 5 Day StorageOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Device: INTERCEPT Blood System for Platelets with LED Illuminator | Healthy Subjects | 40 | 2025-06-02actual | — | 2026-08-04 |
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsNCT03459287results2025-09-10Percentage of Patients Who Have Received at Least One Study Transfusion With a Diagnosis of Renal Impairment Defined as:Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Completed | Device: INTERCEPT, Control | Anemia | 581 | 2023-12-04actual | — | 2025-09-10 |
| In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 DaysNCT04022889results2022-10-27Post Infusion Recovery of Test Platelets at End of Storage (Day 7)Randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Device: INTERCEPT Treated Platelets | Healthy | 37 | 2021-04-16actual | — | 2022-10-27 |
| A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus DiseaseNCT02295501Proportion of subjects who survive EVDOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated on expiry of the frozen and stored plasma components. | Biological: INTERCEPT Plasma | Acute Ebola Virus Disease | 6 | Dec 2020actual | — | 2021-03-29 |
| A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet ComponentsNCT02549222observationalProportion of patients requiring treatment-emergent assisted mechanical ventilation during the study observation period. | — | Completed | Other: Standard of Care | Transfusion Related Acute Lung Injury | 2,291 | Sep 2020actual | — | 2022-02-18 |
| Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC TransfusionNCT01740531Primary Efficacy Endpoint - Hemoglobin consumptionRandomized · Double-masked · Other | Phase 3 | Completed | Biological: S-303 Treated Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells | Thalassemia Major | 86 | 2017-12-21actual | — | 2018-07-18 |
| A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet ComponentsNCT02305732results2018-10-30observationalThe Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets. | — | Completed | Biological: INTERCEPT Platelets | Chikungunya Virus, Dengue Virus | 90 | May 2016actual | — | 2018-10-30 |
| A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo StudyNCT02653443Post infusion recovery of the Test platelets compared to fresh platelets.Randomized · Open-label · Other | Phase 2 | Terminated | Biological: Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components | Healthy | 14 | May 2016actual | — | 2018-01-26 |
| A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% PlasmaNCT02310412Post infusion recovery ratio of Test platelets at Day 7 compared to fresh plateletsRandomized · Open-label · Other | Phase 2 | Completed | Biological: INTERCEPT treated platelets | Healthy | 14 | May 2015actual | — | 2017-11-08 |
| A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood CellsNCT01711346Primary Efficacy: 24 hour post-infusion recovery of autologous Red Blood Cells (RBCs) stored for 35 daysRandomized · Single-masked | Phase 2 | Completed | Biological: S303 Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells (RBCs) | Focus: Assess Post Infusion Viability of S303 RBCs | 42 | Jul 2014actual | — | 2015-12-16 |
| Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute AnemiaNCT01716923Primary Efficacy Endpoint - mean hemoglobin contentRandomized · Triple-masked | Phase 3 | Completed | Biological: S-303 Red Blood Cells (RBCs) - Test, Conventional, untreated red blood cells (RBCs) - Control | Focus:Use of S303 RBCs in Patients With Acute Anemia | 81 | Jul 2014actual | — | 2015-08-26 |
| Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven DaysNCT002619241 hour corrected count increment for plateletsRandomized · Triple-masked · Prevention | Phase 3 | Completed | Device: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days | Thrombocytopenia | 211 | Jul 2009actual | — | 2010-04-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19